Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia
Information source: Shaheed Beheshti Medical University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetic Macular Ischemia
Intervention: enalapril (Drug); oxygen (Other); placebo (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Shaheed Beheshti Medical University Overall contact:
Masoud Soheilian, MD, Phone: +982122585952, Email: labbafi@hotmail.com
Summary
In this study, patients were divided into 3 group with 35 cases including: 1. oxygen
2. enalapril 3. control.
In the beginning of the study, best corrected visual acuity (BCVA), uncorrected visual
acuity (UCVA), and optical coherence tomography (OCT) were measured. Patients in the oxygen
group were given oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the
second month and every other day at the third month. In the enalapril group, patients were
given enalapril 5 mg every night and placebo was given for the patients in third group. At
the end of first month the patients' vision was checked again and at the the end of the
third month the first physical examinations were performed. In the first group, arterial
blood gas (ABG) was taken before and after oxygen therapy as well.
Clinical Details
Official title: Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia
Study design: N/A
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients diagnosed with diabetic macular ischemia
Exclusion Criteria:
- HTN > 1140/90 or HTN controlled by ACE inhibitors
- FBS > 200
- Severe anemia, COPD, cataract, HRPDR and diffuse macular edema
Locations and Contacts
Masoud Soheilian, MD, Phone: +982122585952, Email: labbafi@hotmail.com
Ophthalmic Research Center, Tehran 166666, Iran, Islamic Republic of; Recruiting
Masoud Soheilian, MD, Phone: +98 21 22585952, Email: labbafi@hotmail.com
Additional Information
Last updated: May 11, 2009
|
